Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

Raajit K. Rampal, MD, PhD, discusses promising data on navtemadlin plus ruxolitinib for patients with myelofibrosis who had suboptimal responses to ruxolitinib, showing significant improvements in spleen and symptom responses, with further phase 3 studies anticipated.

Related Content:

Year in Review: Updates in Treating MyelofibrosisMyeloproliferative NeoplasmsHematologic Oncology

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

Dr Hernández-Boluda on the Rationale for Using Machine Learning to Predict Post-HCT Outcomes in Myelofibrosis